Get the Stockscreener App
86.22
0.55%
0.47
After Hours:
85.68
-0.54
-0.63%
Disc Medicine Inc stock is traded at $86.22, with a volume of 252.82K.
It is up +0.55% in the last 24 hours and up +30.48% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$85.75
Open:
$85.88
24h Volume:
252.82K
Relative Volume:
0.60
Market Cap:
$3.00B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-23.49
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
+0.69%
1M Performance:
+30.48%
6M Performance:
+74.46%
1Y Performance:
+92.37%
1-Day Range:
$84.52
$87.00
1-Week Range:
$83.95
$89.79
52-Week Range:
$30.82
$95.95
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
86.22 | 3.21B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Morgan Stanley Issues Positive Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine stock reiterated Strong Buy at Raymond James on DISC-0974 potential - Investing.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Disc Medicine to Participate in Upcoming Investor Conferences - Enidnews.com
Disc Medicine (NASDAQ: IRON) to appear at Guggenheim, Stifel, Jefferies; live webcasts - Stock Titan
Is Disc Medicine Inc. stock trading near support levelsJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Can Disc Medicine Inc. stock weather global recession2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Is Disc Medicine Inc. stock in correction or buying zone2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com
Why Disc Medicine Inc. stock is considered a top pick2025 Year in Review & Low Risk High Reward Trade Ideas - newser.com
Will Disc Medicine Inc. stock maintain growth storyQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What valuation multiples suggest for Disc Medicine Inc. stockEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Applying Wyckoff theory to Disc Medicine Inc. stock2025 Sector Review & Stock Portfolio Risk Control - newser.com
WilmerHale Advises Underwriters in $287.5 Million Public Offering of Disc Medicine - WilmerHale
IRON Stock: Morgan Stanley Raises Price Target to $115 | IRON St - GuruFocus
Morgan Stanley Raises Price Target on Disc Medicine to $115 From $90, Keeps Overweight Rating - MarketScreener
Chronic Kidney Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Jiangsu HengRui, Disc Medicine, 3SBio, Kind Pharma, Jiangsu Hansoh Pharm - Barchart.com
Disc Medicine (IRON): Evaluating Valuation After New Clinical Trial Plans and FDA Recognition Boost Pipeline Momentum - Yahoo Finance
Disc Medicine planning trial of iron overload treatment for sickle cell - Sickle Cell Disease News
Aug Chart Watch: Why Disc Medicine Inc. stock is considered a top pickQuarterly Earnings Summary & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Top chart patterns to watch in Disc Medicine Inc.July 2025 Breakouts & Consistent Profit Focused Trading Strategies - newser.com
How Disc Medicine Inc. stock performs in interest rate cycles2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment - TipRanks
Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera - TipRanks
Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease - TipRanks
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? - sharewise.com
Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors - TipRanks
Disc Medicine’s Promising EPP Treatment Study: Key Updates and Market Impact - TipRanks
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):